Ignite Creation Date:
2025-12-24 @ 12:34 PM
Ignite Modification Date:
2025-12-27 @ 10:07 PM
Study NCT ID:
NCT01709461
Status:
UNKNOWN
Last Update Posted:
2012-10-18
First Post:
2012-10-14
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Continuation Treatment Protocol for Patients Who Participated in the Adagio TVP 1012/501 Clinical Trial
Sponsor:
Rabin Medical Center
Organization:
Study Overview
Official Title:
Continue Providing Care for Patient Who Participated in the Adagio TVP 1012/501 Clinical Trial
Status:
UNKNOWN
Status Verified Date:
2012-06
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
the purpose of the study is to extend the use of Rasagelin Mesylate 1mg per day by subjects who participated in the Adagio TVP 1012/501 according to form 4a for additional three years.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: